RxDoctor Payments DataLook up a doctor →

Thaddeus Beeker, MD

Hematology & Oncology · Mobile, ALNPI 1780637579

Payments from drug & device makers

$195,338in general payments, 2019–2025

Across 445 payments — averaging $438.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$139K
  • Eli Lilly$47K
  • Pfizer$3K
  • Novartis$1K
  • Bristol Myers Squibb$675
  • AstraZeneca$536
  • plus $5K from 48 others
$2,043in research payments, 2019–2025

Across 1 payment — averaging $2042.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck40$138,663
Eli Lilly5$46,829
Pfizer41$2,831
Novartis57$1,062
Bristol Myers Squibb31$675
AstraZeneca(2 entities)31$536
Genentech USA, Inc.22$470
Johnson & Johnson18$411
E.r. Squibb & Sons, L.L.C.24$379
Sanofi12$347
Amgen20$328
Incyte Corporation14$271
Regeneron Healthcare Solutions, Inc.10$241
Astellas Pharma US Inc9$240
Lilly USA, LLC11$185
Daiichi Sankyo Inc.9$175
Eisai Inc.8$153
Stemline Therapeutics Inc.6$143
Exelixis Inc.6$106
Coherus Oncology, Inc.4$92
Ipsen Biopharmaceuticals, Inc4$89
Bayer5$81
Sanofi-aventis U.S. LLC1$79
Beigene USA, Inc.5$67
Gilead4$59
Seagen Inc.3$59
ADC Therapeutics America, Inc.3$56
Azurity Pharmaceuticals, Inc.3$45
GSK3$44
Takeda Pharmaceuticals U.S.A., Inc.3$42
Pharmacosmos Therapeutics Inc.2$39
Progenics Pharmaceuticals, Inc.2$37
Array Biopharma Inc2$37
AbbVie(2 entities)2$36
Tersera Therapeutics LLC1$35
Morphosys, US Inc.2$33
EUSA Pharma (US) LLC2$32
Tesaro, Inc.2$31
Sobi, Inc1$28
EMD Serono, Inc.2$27
Acrotech Biopharma Inc.2$26
Beone Medicines USA, Inc.1$23
Karyopharm Therapeutics Inc.1$23
Pharming Healthcare, Inc.1$22
AVEO Pharmaceuticals, Inc.1$19
Deciphera Pharmaceuticals Inc.1$18
Puma Biotechnology, Inc.1$17
Apellis Pharmaceuticals, Inc.1$17
Boehringer Ingelheim1$15
AMAG Pharmaceuticals, Inc.1$15
Genmab U.S., Inc.1$14
Verastem, Inc.1$13
Veracyte, Inc.1$11
Teva Pharmaceuticals USA, Inc.1$11

How this compares

$195,338 in reported general payments places this provider in the 75th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Medicare billing

Part B allowed, 2024
$84,267
Medicare patients
312
Services billed
1,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Mobile

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →